China turnaround fuels a faster lab recovery
- Q3 core revenue rose 7.3%, beating expectations and leading management to raise full-year guidance.
- China demand rebounded with 9% growth, removing a major overhang from the stock.
- Pharma reshoring is driving new orders, with five of the top ten global pharma companies signing deals in Q3.
- Academia and government customers remain the clearest demand weak spot, declining 3% in the quarter.
- The Biocare acquisition successfully closed and immediately contributed $10 million in revenue.
Growth accelerates as China wakes up
Agilent is executing well ahead of its earlier cycle expectations. In Q3 FY2026, core revenue grew 7.3%, prompting management to raise its full-year core growth target to 5.8% to 6%. Pharma demand remains strong at 12% growth, and the CDMO business is growing nearly 30%.
The bull case gained two major pillars this quarter. First, China returned to 9% growth, easily beating the flat performance analysts expected. Second, the multi-year trend of bringing pharmaceutical manufacturing back home is turning into tangible revenue. Agilent secured reshoring orders from half of the world's top ten pharma companies in Q3 alone.
The bear case still has teeth, though it is shrinking. Academia and government spending remains a persistent drag, falling 3% overall in Q3. The CDMO business faces tough comparisons next quarter before its new Train C capacity ramps up in 2027. Additionally, a significant tax rate headwind remains in place for the full fiscal year.
The Biocare acquisition has closed and contributed $10 million in the quarter. This adds a new clinical diagnostics growth path, but management must now prove it can integrate the business smoothly while managing global tax and tariff pressures.
Sell the lab, then service it
Agilent makes money by selling lab instruments, software, services, and consumables. A customer may buy a chromatography or mass spectrometry machine first. After that, the lab still needs columns, parts, repairs, training, compliance work, and software.
That installed base matters. Agilent CrossLab sells services and consumables across many customer types, and much of the consumables and services portfolio is vendor neutral. That means Agilent can help a lab even when the lab uses some equipment made by another company.
The model can break when customers delay big equipment buys. Universities, government labs, and some funded research groups can stretch old instruments instead of replacing them. Pharma and chemical customers can also cut capital spending if their own markets slow.
Tools across the lab bench
Liquid chromatography and mass spectrometry
These tools help labs separate, identify, and measure chemicals and biological samples. Q3 growth in Life Sciences was led by strong pharma demand for these systems.
Gas chromatography and applied instruments
These systems test chemicals, food, water, fuels, and materials. Applied Markets demand remains solid, supported by chemical and advanced materials testing.
Agilent CrossLab services and consumables
CrossLab sells repairs, maintenance, training, compliance support, software, and lab supplies. It gives Agilent a highly repeatable revenue stream.
Diagnostics and pathology solutions
This group supports cancer diagnostics, tissue staining, companion diagnostics, genomics, and clinical workflows.
Agilent Advanced Therapeutics
This contract manufacturing business makes active pharmaceutical ingredients. It grew nearly 30% in Q3, with more capacity coming online in 2027.
Biocare
A recently closed acquisition in clinical and research solutions. It is now actively contributing to the pathology and clinically focused antibody menu.
CrossLab is the largest slice
Segment mix uses Q2 FY2026 revenue for the three months ended April 30, 2026, as full Q3 segment mix reporting remains pending. CrossLab remains a highly stable core.
What could trip the recovery
Academia and government keep cutting equipment
Medium impact · High oddsAgilent says academia and government revenue declined 3% in Q3. These customers often use funding to keep existing labs running instead of buying new capital equipment. If this lasts, it can drag down total growth.
Tax rules pressure EPS
Medium impact · High oddsAgilent has guided for a higher FY2026 tax rate because of new international tax rules, including OECD Pillar Two. The company expects a 14.5% tax rate and about a three percentage point headwind to EPS growth.
Tariffs and trade costs return
Medium impact · Medium oddsManagement has raised the expected net cost from tariffs for fiscal 2025 to approximately $20 million. While the company feels confident it can mitigate these impacts in FY2026, trade rules remain fluid.
Biocare integration stumbles
Medium impact · Medium oddsAgilent recently closed its $950 million acquisition of Biocare. The deal brings strong clinical assets, but integration can be messy. A slow integration would weaken a key growth catalyst.
In one breath
What does Agilent Technologies do?
Agilent sells tools used by labs to test chemicals, drugs, biological samples, food, water, and materials. Its products include instruments, software, services, consumables, diagnostics tools, and genomics solutions.
Why is Agilent tied to pharma and biotech spending?
Drug companies use Agilent systems to develop, test, and manufacture therapies. When pharma and biotech customers spend more on lab work and equipment, Agilent usually benefits.
Why does Agilent CrossLab matter?
CrossLab sells services and consumables after instruments are already in the lab. That makes revenue steadier because labs still need repairs, parts, maintenance, and compliance support regardless of new equipment budgets.
What is the biggest near-term risk for Agilent?
The main demand risk is weak academia and government spending. The main earnings risks are that tax regulations and tariff costs hide the improvement in core demand.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Agilent Technologies, Inc. in Finn's Diagnostics & Research industry ranking.
